Care of Patients Receiving Abemaciclib: Results From Clinical Trials and a Healthcare Provider Survey

BACKGROUND: Being familiar with the care of patients with breast cancer who are receiving abemaciclib, including adverse event (AE) management, supports care. OBJECTIVES: This article describes the care of patients with breast cancer receiving abemaciclib, including AE data from clinical trials and nonpharmacologic interventions in real-world practice through a survey of healthcare providers. METHODS: Safety data from the monarchE, MONARCH 1, MONARCH 2, and MONARCH 3 trials were reviewed. A quantitative survey of advanced practitioners, oncologists, and pharmacists was also conducted to better understand nonpharmacologic interventions to manage patient-felt AEs and support patients receiving abemaciclib. FINDINGS: The most common AEs across all MONARCH trials were diarrhea, fatigue, nausea, and neutropenia; most events were grade 1–2. Of 282 survey respondents, more than 90% recommended nonpharmacologic interventions to manage AEs.